Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA ramps up GMP inspections

This article was originally published in The Tan Sheet

Executive Summary

FDA plans to increase its inspections of supplement firms' compliance with good manufacturing practices as the June compliance date approaches for small companies, those with up to 20 employees. Stephen Sundlof, Center for Food Safety and Applied Nutrition director, said other "pressing needs for inspections," such as salmonella-tainted peanut products, have had the agency's attention. However, CFSAN "will be going back and looking at the compliance of the industry with GMPs now that they are mandatory," he said at the Food and Drug Law Institute's annual conference April 22. FDA's June 2007 supplement GMP final 1rule required firms with 500 or more employees to be in compliance a year later and those with more than 20 employees by June 2009 (2"The Tan Sheet" May 11, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel